Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04757610
Other study ID # OPT-302-1004
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 12, 2021
Est. completion date July 2026

Study information

Verified date March 2024
Source Opthea Limited
Contact Opthea Limited
Phone +61 3 9826 0399
Email info@opthea.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.


Recruitment information / eligibility

Status Recruiting
Enrollment 990
Est. completion date July 2026
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye. - An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye. Main Exclusion Criteria: - Any previous treatment for neovascular AMD. - Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging. - Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
2.0 mg OPT-302
intravitreal injection
0.5 mg ranibizumab
intravitreal injection
Procedure:
Sham
intravitreal injection

Locations

Country Name City State
Argentina ShORe Investigational Site Buenos Aires
Argentina ShORe Investigational Site Buenos Aires
Argentina ShORe Investigational Site Capital federal Ciudad Autonoma Buenos Aires
Argentina ShORe Investigational Site Ciudad Autonoma de Buenos Aire
Argentina ShORe Investigational Site Córdoba
Argentina ShORe Investigational Site Rosario Santa Fe
Argentina ShORe Investigational Site Rosario Sante Fe
Australia ShORe Investigational Site Hurstville New South Wales
Australia ShORe Investigational Site Melbourne Victoria
Brazil ShORe Investigational site Blumenau Santa Catarina
Brazil ShORe Investigational Site Faxinal do Soturno Rio Grande Do Sul
Brazil ShORe Investigational Site Goiânia Goias
Brazil ShORe Investigational Site Santo André Sao Paulo
Brazil ShORe Investigational Site São Paulo
Brazil ShORe Investigational Site São Paulo
Brazil ShORe Investigational Site Vitória Cordoba
Bulgaria ShORe Investigational Site Sofia
Canada ShORe Investigational Site Calgary Alberta
Canada ShORe Investigational Site Calgary Alberta
Canada ShORe Investigational Site Edmonton Alberta
Canada ShORe Investigational Site Edmonton Alberta
Canada ShORe Investigational Site Mississauga Ontario
Colombia ShORe Investigational Site Medellín
Czechia ShORe Investigational Site Pardubice
Czechia ShORe Investigational Site Praha
Czechia ShORe Investigational Site Praha
Czechia ShORe Investigational Site Sokolov
Denmark ShORe Investigational Site Aarhus
Denmark ShORe Investigational Site Glostrup
Denmark ShORe Investigational Site Sønderborg
France ShORe Investigational Site Créteil Val De Marr
France ShORe Investigational Site Écully Rhone
France ShORe Investigational Site Nice Alpes-Maritimes
France ShORe Investigational Site Strasbourg Bas Rhin
Germany ShORe Investigational Site Bonn Nordrhein Westfalen
Germany ShORe Investigational Site Düsseldorf Nordrhein
Germany ShORe Investigational Site Goettigen Niedersachsen
Germany ShORe Investigational Site Hamburg
Germany ShORe Investigational Site Heidelberg Baden Wuerttemberg
Germany ShORe Investigational Site Münster Nordrhein Westfalen
Germany ShORe Investigational Site Münster Nordrhein
Germany ShORe Investigational Site Ulm Baden Wuerttermberg
Greece ShORe Investigational Site Athens
Greece ShORe Investigational Site Ioánnina
Greece ShORe Investigational Site Patra
Hungary ShORe Investigational Site Budapest
Hungary ShORe Investigational Site Miskolc
Hungary ShORe Investigational Site Szombathely
India ShORe Investigational Site Ahmedabad Gujarat
India ShORe Investigational Site Bangalore Karnataka
India ShORe Investigational Site Bangalore Karnataka
India ShORe Investigational Site Chandigarh Punjab
India ShORe Investigational Site Coimbatore Tamilnadu
India ShORe Investigational Site Kolkata West Bengal
India ShORe Investigational Site Lucknow Uttar Pradesh
India ShORe Investigational Site Mysuru
India ShORe Investigational Site Pune Maharashtra
India ShORe Investigational Site Surat Gujarat
Israel ShORe Investigational Site Be'er Sheva
Israel ShORe Investigational Site Haifa
Israel ShORe Investigational Site Kfar-Sava
Israel ShORe Investigational Site Petach Tikva
Israel ShORe Investigational Site Rishon LeZion
Italy ShORe Investigational Site Bologna
Italy ShORe Investigational Site Catanzaro Reggio Calabria
Italy ShORe Investigational Site Chieti
Italy ShORe Investiagational Site Genova
Italy ShORe Investigational Site Roma
Italy ShORe Investigational Site Siena
Italy ShORe Investigational Site Udine
Korea, Republic of ShORe Investigational Site Busan
Korea, Republic of ShORe Investigational Site Busan
Korea, Republic of ShORe Investigational Site Daegu Gyeongsangbuk-do
Korea, Republic of ShORe Investigational Site Gwangju
Korea, Republic of ShORe Investigational Site Seongnam Gyeonggi-do
Korea, Republic of ShORe Investigational Site Seoul
Korea, Republic of ShORe Investigational Site Seoul
Korea, Republic of ShORe Investigational Site Seoul
Korea, Republic of ShORe Investigational Site Seoul
Korea, Republic of ShORe Investigational Site Seoul
Korea, Republic of ShORe Investigational Site Seoul
Latvia ShORe Investigational Site Riga
Malaysia ShORe Investigational Site Batu Caves Selangor
Malaysia ShORe Investigational Site Kuala Lumpur
Malaysia ShORe Investigational Site Shah Alam Selangor
Poland ShORe Investigational Site Gdansk
Poland ShORe Investigational Site Kraków
Poland ShORe Investigational Site Olsztyn
Poland ShORe Investigational Site Szczecin
Poland ShORe Investigational Site Tarnowskie Góry
Poland ShORe Investigational Site Warsaw
Poland ShORe Investigational Site Wroclaw
Spain ShORe Investigational Site Alcala de Henares Madrid
Spain ShORe Investigational Site Barcelona
Spain ShORe Investigational Site Barcelona
Spain ShORe Investigational Site Burgos
Spain ShORe Investigational Site Burjassot Valencia
Spain ShORe Investigational Site Córdoba
Spain ShORe Investigational Site Madrid
Spain ShORe Investigational Site Madrid
Spain ShORe Investigational Site Pamplona Navarra
Spain ShORe Investigational Site Sant Cugat Del Vallès Barcelona
Spain ShORe Investigational Site Valencia
Thailand ShORe Investigational Site Chiang Mai
Thailand ShORe Investigational Site Khon Kaen
Thailand ShORe Investigational Site Pathum Thani
Thailand ShORe Investigational Site Pathum Wan Bangkok
Ukraine ShORe Investigational Site Kiev
United Kingdom ShORe Investigational Site Bristol Somerset
United Kingdom ShORe Investigational Site Crewe Cheshire
United Kingdom ShORe Investigational Site Guildford Surrey
United Kingdom ShORe Investigational Site Leicester Leicestershire
United Kingdom ShORe Investigational Site London
United Kingdom ShORe Investigational Site London
United Kingdom ShORe Investigational Site Southampton Hampshire
United Kingdom ShORe Investigational Site Wolverhampton West Midlands
United States ShORe Investigational Site Arlington Texas
United States ShORe Investigational Site Augusta Georgia
United States ShORe Investigational Site Austin Texas
United States ShORe Investigational Site Austin Texas
United States ShORe Investigational Site Bakersfield California
United States ShORe Investigational Site Baltimore Maryland
United States ShORe Investigational Site Baltimore Maryland
United States ShORe Investigational Site Beaufort South Carolina
United States ShORe Investigational Site Bellaire Texas
United States ShORe Investigational Site Bloomfield New Jersey
United States ShORe Investigational Site Campbell California
United States ShORe Investigational Site Charlottesville Virginia
United States ShORe Investigational Site Clearwater Florida
United States ShORe Investigational Site Colorado Springs Colorado
United States ShORe Investigational Site Dallas Texas
United States ShORe Investigational Site Denver Colorado
United States ShORe Investigational Site Edmond Oklahoma
United States ShORe Investigational Site Encino California
United States ShORe Investigational Site Erie Pennsylvania
United States ShORe Investigational Site Eugene Oregon
United States ShORe Investigational Site Fargo North Dakota
United States ShORe Investigational Site Fort Lauderdale Florida
United States ShORe Investigational Site Fort Myers Florida
United States ShORe Investigational Site Fullerton California
United States ShORe Investigational Site Gainesville Florida
United States ShORe Investigational Site Glendale California
United States ShORe Investigational Site Hagerstown Maryland
United States ShORe Investigational Site Hauppauge New York
United States ShORe Investigational Site Houston Texas
United States ShORe Investigational Site Huntington Beach California
United States ShORe Investigational Site Indianapolis Indiana
United States ShORe Investigational Site Katy Texas
United States ShORe Investigational Site Ladson South Carolina
United States ShORe Investigational Site Laguna Hills California
United States ShORe Investigational Site Lakeland Florida
United States ShORe Investigational Site Lakewood Colorado
United States ShORe Investigational Site Lemont Illinois
United States ShORe Investigational Site Liverpool New York
United States ShORe Investigational Site Long Beach California
United States ShORe Investigational Site Longmont Colorado
United States ShORe Investigational Site Los Angeles California
United States ShORe Investigational Site Lynchburg Virginia
United States ShORe Investigational Site McAllen Texas
United States ShORe Investigational Site Minneapolis Minnesota
United States ShORe Investigational Site Mountain View California
United States ShORe Investigational Site Nashville Tennessee
United States ShORe Investigational Site Palm Desert California
United States ShORe Investigational site Pasadena California
United States ShORe Investigational Site Pensacola Florida
United States ShORe Investigational Site Phoenix Arizona
United States ShORe Investigational Site Phoenix Arizona
United States ShORe Investigational Site Pinellas Park Florida
United States ShORe Investigational Site Portland Oregon
United States ShORe Investigational Site Portland Oregon
United States ShORe Investiagtional Site Poway California
United States ShORe Investigational Site Redlands California
United States ShORe Investigational Site Reno Nevada
United States ShORe Investigational Site Sacramento California
United States ShORe Investigational Site Saint Louis Missouri
United States ShORe Investigational Site Salem Oregon
United States ShORe Investigational Site Salt Lake City Utah
United States ShORe Investigational Site San Antonio Texas
United States ShORe Investigational Site San Antonio Texas
United States ShORe Investigational Site San Antonio Texas
United States ShORe Investigational Site Sandy Springs Georgia
United States ShORe Investigational Site Santa Ana California
United States ShORe Investigational Site Springfield Massachusetts
United States ShORe Investigational Site Temple Terrace Florida
United States ShORe Investigational Site Toms River New Jersey
United States ShORe Investigational Site Torrance California
United States ShORe Investigational Site Towson Maryland
United States ShORe Investigational Site Tucson Arizona
United States ShORe Investigational Site Tulsa Oklahoma
United States ShORe Investigational Site Tyler Texas
United States ShORe Investigational Site Wake Forest North Carolina
United States ShORe Investigational Site Willow Park Texas

Sponsors (1)

Lead Sponsor Collaborator
Opthea Limited

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  Bulgaria,  Canada,  Colombia,  Czechia,  Denmark,  France,  Germany,  Greece,  Hungary,  India,  Israel,  Italy,  Korea, Republic of,  Latvia,  Malaysia,  Poland,  Spain,  Thailand,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) letters Baseline to Week 52
Secondary Proportion of participants gaining 15 or more ETDRS BCVA letters Baseline to Week 52
Secondary Proportion of participants gaining 10 more ETDRS BCVA letters Baseline to Week 52
Secondary Change in choroidal neovascularisation (CNV) area by fluorescein angiography (FA) Baseline to Week 52
Secondary Proportion of participants with absence of both sub-retinal fluid and intra-retinal cysts by SD-OCT Baseline to Week 52
See also
  Status Clinical Trial Phase
Recruiting NCT04101877 - The Sahlgrenska Anti-VEGF Study Phase 2
Completed NCT03953079 - A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Phase 2
Terminated NCT03577899 - Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) Phase 3
Completed NCT02867735 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema Phase 1
Completed NCT01926977 - Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration Phase 1/Phase 2
Recruiting NCT00370539 - Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD Phase 3
Recruiting NCT03683251 - Extension Study for the Port Delivery System With Ranibizumab (Portal) Phase 3
Completed NCT03909425 - Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography
Completed NCT03744767 - Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration Phase 2
Recruiting NCT04690556 - Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD Phase 3
Completed NCT05281042 - Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study
Completed NCT03677934 - A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration Phase 3
Recruiting NCT03594461 - Intense Treatment Regimen With Intravitreal Aflibercept Injection Phase 1/Phase 2
Completed NCT05131646 - Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
Completed NCT04537884 - Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration Phase 1
Completed NCT03216538 - Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Completed NCT04304755 - Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD) Phase 2
Completed NCT01958918 - Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Phase 4
Active, not recruiting NCT01918878 - Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. Phase 4
Completed NCT01712035 - Neovascular Age-related Macular Degeneration